Mr. Arun Menawat reports

TEXAS PROSTATE AND DALLAS MEDICAL CENTER LAUNCH FIRST-OF-ITS-KIND TULSA PROGRAM, EXPANDING ACCESS TO ADVANCED PROSTATE TREATMENT

Texas Prostate and Dallas Medical Center have launched a first-of-its-kind Tulsa program to meet the growing demand for advanced prostate treatment -- without surgery. Under the program, Texas Prostate will perform Profound Medical Corp.'s Tulsa procedures for men with prostate cancer and benign prostatic hyperplasia (BPH) in Dallas Medical Center's state-of-the-art MRI (magnetic resonance imaging) suite, significantly expanding Medicare patient access to the Tulsa procedure.

"The Tulsa procedure is integral to our practice because it offers many men effective prostate treatment without the life-altering side effects of surgery -- such as incontinence or erectile dysfunction," said Dr. James Cochran, founder of Texas Prostate. "With Medicare coverage now available, we've been seeking ways to offer more men access to this transformative technology. Working with Dallas Medical Center allows us to do just that."

In January, 2025, Medicare coverage was granted for the Tulsa procedure performed in hospital outpatient, ambulatory surgical centre and private office/non-facility settings, broadening access to the treatment. This collaboration makes the Tulsa procedure available under Medicare coverage, with Texas Prostate now performing Tulsa procedures exclusively at Dallas Medical Center. The hospital gains both advanced technology and the Texas Prostate team's proven expertise in performing Tulsa procedures.

"At Dallas Medical Center, we're committed to bringing advanced, compassionate care to our patients," said Ruben Garza, chief executive officer of Dallas Medical Center. "By working with Texas Prostate, patients can be treated with the Tulsa-Pro system in our state-of-the-art MRI suite and then return home the same day, with no procedural blood loss and a significantly lower risk of complications."

Profound Medical chief executive officer Arun Menawat added: "The versatility of Tulsa enables the treatment of a wide variety of prostate disease, including whole-gland or targeted-gland treatments, and we are thrilled to see that this new program will provide access to a wider population of patients. Importantly, it also provides a model for private-pay urology practices and Medicare accepting hospitals nationwide seeking to expand access to the Tulsa procedure."

The Tulsa procedure represents a major advancement in prostate care. Unlike traditional treatments that involve surgery, radiation or lengthy recovery times, the Tulsa procedure is performed inside an MRI suite using robotically guided, directional ultrasound to precisely ablate targeted prostate tissue -- without harming surrounding structures. The Tulsa-Pro system -- the technology behind the procedure -- is the only artificial-intelligence-powered, MRI-guided robotic system for prostate treatment. It allows physicians to visualize the prostate in real time and customize therapy for each patient with unmatched precision.

About Profound Medical Corp.

Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.

Profound is commercializing Tulsa-Pro, a technology that combines real-time MRI, AI-enhanced planning, robotically driven transurethral ultrasound and closed-loop temperature feedback control. The Tulsa procedure, performed using the Tulsa-Pro system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum, ranging from low-, intermediate- or high-risk prostate cancer to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (BPH), to men with BPH only, and also to patients requiring salvage therapy for radio-recurrent localized prostate cancer. Tulsa employs real-time MR (magnetic resonance) guidance for precision to preserve patients' urinary continence and sexual function while killing the targeted prostate tissue through precise sound absorption technology that gently heats it to 55 to 57 C. Tulsa is an incision- and radiation-free one-and-done procedure performed in a single session that takes a few hours. Virtually all prostate shapes and sizes can be safely, effectively and efficiently treated with Tulsa. There is no bleeding associated with the procedure; no hospital stay is required; and most Tulsa patients report quick recovery to their normal routines. Tulsa-Pro is CE (Conformite Europeenne) marked, Health Canada approved, and 510(k) cleared by the U.S. Food and Drug Administration (FDA).

Profound is also commercializing Sonalleve, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases. Sonalleve has also been approved by the China National Medical Products Administration for the non-invasive treatment of uterine fibroids and has FDA approval under a humanitarian device exemption for the treatment of osteoid osteoma. Profound is in the early stages of exploring additional potential treatment markets for Sonalleve where the technology has been shown to have clinical application, such as non-invasive ablation of abdominal cancers and hyperthermia for cancer therapy.

We seek Safe Harbor.